Herbs (Global Traditional) · Amazonian
Suma (Hebanthe eriantha) (Hebanthe eriantha)
Moderate Evidencebotanical1 PubMed Study
Hermetica Superfood Encyclopedia
Suma (Hebanthe eriantha) contains ecdysterone and pfaffic acid as primary bioactive compounds. These compounds demonstrate anti-cancer and anti-inflammatory effects through inhibition of tumor cell proliferation and reduction of inflammatory mediators.
Suma (Hebanthe eriantha) is a perennial vine native to Brazil, Peru, and Venezuela, where its roots are harvested for medicinal use. The roots are typically extracted using methanol, ethanol, or water to yield crude extracts containing pfaffosides and flavonoids, with no standardized commercial extraction method currently established.
No human clinical trials, RCTs, or meta-analyses have been conducted on Suma. All evidence comes from preclinical studies including in vitro cytotoxicity assays (PMID: 37337697) and rodent models of inflammation and cancer (PMID: 10917139). The lack of human studies significantly limits clinical applicability.
No clinically studied human dosages exist. Preclinical studies used 300 mg/kg oral doses of ethanol extract in rodents for anti-inflammatory effects, and 88.5-272.6 µg/mL concentrations in vitro for anticancer activity. Consult a healthcare provider before starting any new supplement.
Suma root (Hebanthe eriantha) is notably rich in bioactive compounds rather than conventional macronutrients. Key constituents include: • Pfaffic acid and pfaffosides (triterpenoid saponins): approximately 11% total saponin content by dry weight, with pfaffosides A, B, C, D, E, and F being the principal glycosides; pfaffic acid (a nortriterpene) is considered the primary bioactive compound linked to antiproliferative activity • Ecdysteroids: notably beta-ecdysterone (20-hydroxyecdysone) at concentrations of approximately 0.63–0.7% of dry root weight (~6.3–7.0 mg/g); these plant steroids are believed to contribute to adaptogenic and anabolic-like effects • Germanium (organic form): reported at approximately 0.001% (trace levels), which may contribute to oxygen utilization and immune modulation • Minerals: contains notable levels of iron (~15–20 mg/100g dry weight), magnesium (~40–50 mg/100g), zinc (~3–5 mg/100g), cobalt, and silica • Vitamins: contains modest amounts of vitamins A, B1 (thiamine), B2 (riboflavin), E, K, and pantothenic acid, though concentrations are relatively low compared to dietary sources • Amino acids: contains all 19 amino acids; particularly rich in arginine, aspartic acid, and glutamic acid; total protein content of the dried root is approximately 10–11% • Polysaccharides: significant fraction (~3–5% dry weight) of complex polysaccharides including beta-glucans, which may contribute to immunomodulatory effects • Stigmasterol and sitosterol: plant sterols present at approximately 0.1–0.3% dry weight • Allantoin: approximately 0.1% dry weight, a compound associated with cell proliferation and wound healing • Electrolytes and trace elements: potassium, calcium, and phosphorus present in moderate amounts • Fiber content: approximately 20–25% crude fiber in dried root • Bioavailability notes: Pfaffosides are glycosylated saponins with relatively low oral bioavailability unless the sugar moieties are cleaved by gut microbiota to release pfaffic acid aglycone; beta-ecdysterone has moderate oral bioavailability (~25–30% in animal models) with rapid hepatic metabolism; co-administration with lipids may enhance absorption of ecdysteroids and triterpenoids; the high saponin content may itself enhance membrane permeability and absorption of other bioactives
Suma's ecdysterone modulates protein synthesis through activation of PI3K/Akt pathways while inhibiting cancer cell proliferation via cell cycle arrest. Pfaffic acid and other saponins suppress inflammatory mediators including TNF-α and IL-1β through NF-κB pathway inhibition. The compound also affects leukocyte migration and prostaglandin synthesis.
Preclinical studies show suma extracts inhibit colon cancer cells at IC50 272.6 µg/mL and breast tumor cells at IC50 88.5 µg/mL. Animal studies demonstrate 51% reduction in paw edema and 69% reduction in leukocyte infiltration. However, no randomized controlled trials in humans have been published. Current evidence is limited to in vitro and animal models.
Suma is generally well-tolerated with mild gastrointestinal upset reported in some users. No significant drug interactions have been documented, though theoretical interactions with blood thinners may exist due to saponin content. Safety during pregnancy and breastfeeding is unknown. Individuals with hormone-sensitive conditions should exercise caution due to potential estrogenic effects of ecdysterone.
